LifeSemantics Approved for Cardiovascular AI Trial

LifeSemantics made a landmark cardio tech science achievement by receiving the MFDS approval to initiate a post-marketing surveillance (PMS) study. This pivotal study aims to assess the efficacy of its cutting-edge Artificial Intelligence (AI) software in evaluating risks associated with hypertension complications. Revolutionizing cardiovascular risk assessment The study will involve... source: https://www.cryptopolitan.com/lifesemantics-for-cardiovascular-ai-trial/